SK biotek, a Seoul, South Korea-based wholly owned subsidiary of SK Holdings, has set up operations at its active pharmaceutical ingredients (API) facility in Dublin, Ireland, according to IDA Ireland, a semi-state body promoting foreign direct investment into Ireland.

SK biotek acquired the small-molecule API manufacturing facility in Swords, County Dublin, Ireland from Bristol-Myers Squibb in June 2017 and completed the deal by year-end 2017. Over 360 staff employed on the Swords campus, dedicated to API operations, transitioned to SK biotek employment from January 1, 2018.

SK biotek plans to operate and develop the Swords campus as a stand-alone contract development manufacturing organization, which will manufacture pharma products to specification for other pharmaceutical companies on a contract basis. SK biotek also intends to add marketing, research, and development talent while investing to bring additional API manufacturing capacity to the Swords campus.

Source: IDA Ireland